Immunic (NASDAQ:IMUX) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Immunic (NASDAQ:IMUX) in a report issued on Monday, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price target on the stock. HC Wainwright also issued estimates for Immunic’s Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.95) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

Several other equities analysts also recently weighed in on the company. Leerink Partners restated an “outperform” rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. B. Riley assumed coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective for the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research note on Monday, September 16th. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Immunic currently has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Up 5.3 %

Shares of IMUX opened at $1.20 on Monday. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The stock has a market cap of $108.10 million, a P/E ratio of -0.98 and a beta of 1.88. The business’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.34.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Immunic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in Immunic in the 1st quarter valued at $9,266,000. Vanguard Group Inc. grew its stake in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC increased its position in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.